Highlights From ASH
The Advanced Practitioner Perspective
Sandra E. Kurtin, PhD, ANP-C, AOCN, on Multiple Myeloma in Older Patients: Isatuximab With Pomalidomide and Dexamethasone
Sandra E. Kurtin, PhD, ANP-C, AOCN, of the University of Arizona Cancer Center, discusses data from the ICARIA-MM trial that show adding isatuximab to pomalidomide and dexamethasone improved progression-free survival, overall survival, overall response rate, and very good partial response rate in older patients (65 years and older) with relapsed/refractory multiple myeloma (Abstract 1893).
Amy Pierre, ANP-BC, on CLL in Older Patients: The Alliance Trial on Ibrutinib, Obinutuzumab, and Venetoclax
Amy Pierre, ANP-BC, of Memorial Sloan Kettering Cancer Center, discusses a currently enrolling phase III trial on a new strategy to decrease exposure time to ibrutinib, which has the potential to change the standard of care for patients 70 years or older with previously untreated chronic lymphocytic leukemia (Abstract 1751).
Amy Pierre, ANP-BC, on Multiple Myeloma: Autologous Stem Cell Transplant in Older Patients
Amy Pierre, ANP-BC, of Memorial Sloan Kettering Cancer Center, discusses study findings on the decreased use of autologous stem cell transplant in older patients with multiple myeloma, despite the therapy’s significant survival benefit. The study suggests factors that make it more likely patients would forgo the treatment (Abstract 2195).
Sara Tinsley, PhD, APRN, AOCN, on MDS: MEDALIST Trial of Luspatercept to Treat Anemia
Sara Tinsley, PhD, APRN, AOCN, of Moffitt Cancer Center, discusses study findings that showed most patients with lower-risk myelodysplastic syndrome treated with luspatercept, a first-in-class erythroid maturation agent, achieved independence from red blood cell transfusions and/or hematologic improvement (Abstract 841).
Sandra E. Kurtin, PhD, ANP-C, AOCN, on Treating CLL in the Community Setting: Early Discontinuation of First-Line Ibrutinib
Sandra E. Kurtin, PhD, ANP-C, AOCN, of the University of Arizona Cancer Center, discusses the findings of a retrospective study that assessed the use of first-line ibrutinib for chronic lymphocytic leukemia in the United States. Although the agent was increasingly used in this setting, early discontinuation was more common than reported, suggesting clinical decision support tools and care delivery approaches should be explored (Abstract 797).
Sara Tinsley, PhD, APRN, AOCN, on MDS: Oral Rigosertib and Injectable Azacitidine
Sara Tinsley, PhD, APRN, AOCN, of Moffitt Cancer Center, discusses data that show rigosertib and azacitidine may provide a potential new first-line treatment for patients with high-risk myelodysplastic syndrome (Abstract 4268).
Sara Tinsley, PhD, APRN, AOCN, on CLL: Therapies After Venetoclax Discontinuation
Sara Tinsley, PhD, APRN, AOCN, of Moffitt Cancer Center, discusses study findings suggesting that BTK inhibitors in naive or previously responsive patients with chronic lymphocytic leukemia and allogeneic hematopoietic stem cell transplantation following venetoclax appear to be effective strategies with durable responses. The data indicate a number of effective regimens for patients after treatment with venetoclax, providing support for using venetoclax earlier in the course of CLL (Abstract 502).
Sandra E. Kurtin, PhD, ANP-C, AOCN, on AML in First Remission: QUAZAR Trial of Oral Azacitidine
Sandra E. Kurtin, PhD, ANP-C, AOCN, of the University of Arizona Cancer Center, discusses phase III findings on oral azacitidine, the first treatment used in the maintenance setting shown to improve both overall and disease-free survival in patients with acute myeloid leukemia that is in remission following induction chemotherapy (Abstract LBA-3).
Amy Pierre, ANP-BC, on Multiple Myeloma: CANDOR Trial of Carfilzomib, Dexamethasone, and Daratumumab
Amy Pierre, ANP-BC, of Memorial Sloan Kettering Cancer Center, discusses phase III study findings that suggest the combination of carfilzomib, dexamethasone, and daratumumab represents an efficacious new regimen for patients with relapsed or refractory disease, including those who are refractory to lenalidomide (Abstract LBA-6).